Fig. 3From: Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in SpainOverall survival (OS) according to systemic inflammation scores (SIS) of a 0, 1, 2 or 3 and b 1–3 vs 0, and progression-free survival (PFS) with vs without antiangiogenic therapy (bevacizumab) in patients with SIS of c 0 and d 1–3Back to article page